The video is very interesting, bringing particular attention to screening for CKD in diabetes. Mentioned is “new tools in the chest” for Drs on screening for kidney disease in diabetes; monitoring eGFR, ACR & albuminuria are not “new tools” but still very important ones, so I really wonder what was alluded to here in relation to SGLT2 inhibitor class of drugs now approved for DKD?
It’s only a short video, I recommend watching it all, but the section on monitoring & screening at 0.39 min is very interesting:
I really think we are getting closer to the goal posts now. Particularly that Canafliglozin is the only drug so far approved for Diabetic kidney disease in SGLT2 class, and what PIQ have a collaboration with Janssen on diagnostics.
You are not going to see hype from the medical community, but PromarkerD has been presented at internationally recognised Diabetes conferences in the USA & published literature & Richard invited as KOL (key opinion leader) in diagnostics, so the information is out there, and the test validated in clinical trials. There has been a lot happening in KOL working parties in the USA recently to attempt to address the problem of CKD & to develop guidelines after Whitehouse policy.
As stated in the video, there is now a whole new ball game for treatment & a change in the landscape of treating diabetic kidney disease & preventing CV disease in diabetes with a new drug available. It’s not for everyone, risks are spoken about in the video.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)